4 unknown, 3 completed. 2 Phase 1, 2 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Phase 4 | 2 | Completed 2 |
| Not applicable | 1 | Unknown 1 |
Follow Glucocorticoids Toxicity: new trials by email Literature Review of Glucocorticoids Toxicity trials Research Report on Glucocorticoids Toxicity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Romosozumab Versus Denosumab in Glucocorticoid-induced Osteoporosis: an Extended Observation of a Randomized Controlled Trial at 48 Months Romosozumab, Denosumab - Osteoporosis, Glucocorticoids Toxicity | Phase 4 | Completed | Tuen Mun Hospital | 54 | 2024-08-20 | 2026-05-05 |
| Effects of Glucocortioids in Human Skeletal Muscle, Adipose Tissue and Skin Prednisolone, Placebo - Glucocorticoids Toxicity, Iatrogenic Effect | Not applicable | Unknown | University of Aarhus | 12 | 2023-12-01 | 2023-11-22 |
| Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects 101-PGC-005 - Glucocorticoids Toxicity, COVID-19 | Phase 1 | Unknown | 101 Therapeutics | 6 | 2022-10-29 | 2022-12-14 |
| Monıtorıng Glucocortıcoıd Treatment In Patıents Followed In Rheumatology Clınıc Glucocorticoids Toxicity, Rheumatoid Arthritis | Unknown | Hacettepe University | 200 | 2021-02-01 | 2022-08-03 | |
| Investigating the Morbidity of Glucocorticoid Use in Patients With Autoimmune Bullous Diseases (AIBDs) GlucoCorticoid - Autoimmune Bullous Dermatosis, Glucocorticoids Toxicity | Unknown | Premier Specialists, Australia | 138 | 2019-02-02 | 2023-08-31 | |
| Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids Prednisone - Glucocorticoids Toxicity, Glucose Intolerance | Phase 1 | Completed | Vanderbilt University Medical Center | 25 | 2017-02-15 | 2020-06-04 |
| Liver Function After Intravenous Methylprednisolone Administration every week IVMP therapy, very high doses IVMP therapy - Graves Disease, Graves Ophthalmopathy | Phase 4 | Completed | Medical University of Warsaw | 68 | 2012-01-01 | 2018-09-13 |
Arthritis, Rheumatoid (1) · COVID-19 (1) · Chemical and Drug Induced Liver Injury (1) · Communicable Diseases (1) · Fractures, Bone (1) · Glucose Intolerance (1) · Graves Disease (1) · Graves Ophthalmopathy (1) · Hepatic Insufficiency (1) · Liver Diseases (1) · Liver Failure (1) · Liver Failure, Acute (1) · Lupus Erythematosus, Systemic (1) · Osteoporosis (1) · Vasculitis (1)
Autoimmune Diseases (2) · Immune System Diseases (2) · Metabolic Diseases (2) · Musculoskeletal Diseases (2) · Nutritional and Metabolic Diseases (2) · Arthritis (1) · Bone Diseases (1) · Bone Diseases, Metabolic (1) · Cardiovascular Diseases (1) · Chemically-Induced Disorders (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Connective Tissue Diseases (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Digestive System Diseases (1)
Denosumab (1) · Drugs, Generic (1) · Glucocorticoids (1) · Prednisolone (1) · Prednisone (1) · romosozumab (1)
101 Therapeutics (1) · Hacettepe University (1) · Medical University of Warsaw (1) · Premier Specialists, Australia (1) · Tuen Mun Hospital (1) · University of Aarhus (1) · Vanderbilt University Medical Center (1)
Australia (1) · China (1) · India (1) · Turkey (Türkiye) (1) · United States (1)
Chi Chiu Mok, MD, FRCP (1) · Dedee Murrell, MBBS (1) · Omer Karadag, prof. doctor (1) · Vivian K Kawai (1)
K23GM117395 (1)